Biomarker ID | 1636 |
PMID | 31031850 |
Year | 2019 |
Biomarker | CDKN3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset
31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.930 |
Effect on Pathways | Pathway include: Golgi-to-ER retrograde transport; Cell Cycle, Mitotic; Mitotic Metaphase and Anaphase; Mitotic Prometaphase; Vesicle-mediated transport |
Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
Type of Biomarker | Prognostic |
Cohort | 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis |
Senstivity | NA |
Specificity | NA |
AUC | 0.702 |
Accuracy | NA |
Level Of Significance | p < 0.0001 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |